Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas

Ramesk K Ramanathan, D. Goldstein, R. L. Korn, F. Arena, M. Moore, S. Siena, L. Teixeira, J. Tabernero, J. L. Van Laethem, H. Liu, D. McGovern, B. Lu, D. D. Von Hoff

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

In the phase III MPACT trial, nab-paclitaxel plus gemcitabine (nab-P + Gem) demonstrated superior efficacyversus Gem alone for patients with metastatic pancreatic cancer. We sought to examine the feasibility of positron emissiontomography (PET) and to compare metabolic response rates and associated correlations with efficacy in the MPACT trial.Patients and methods: Patients with previously untreated metastatic adenocarcinoma of the pancreas were randomized1:1 to receive nab-P + Gem or Gem alone. Treatment continued until disease progression by RECIST or unacceptable toxicity.Results: PET scans were carried out on the first 257 patients enrolled at PET-equipped centers (PET cohort). Most patients(252 of 257) had ≥ 2 PET-avid lesions, and median maximum standardized uptake values at baseline were 4.6 and 4.5 in thenab-P + Gem and Gem-alone arms, respectively. In a pooled treatment arm analysis, a metabolic response by PET (best responseat any time during study) was associated with longer overall survival (OS) (median 11.3 versus 6.9 months; HR, 0.56;P < 0.001). Efficacy results within each treatment arm appeared better for patients with a metabolic response. The metabolicresponse rate (best response and week 8 response) was higher for nab-P + Gem (best response: 72% versus 53%,P = 0.002; week 8: 67% versus 51%; P = 0.014). Efficacy in the PET cohort was greater for nab-P + Gem versus Gem alone,including for OS (median 10.5 versus 8.4 months; hazard ratio [HR], 0.71; P = 0.009) and ORR by RECIST (31% versus 11%;P < 0.001).Conclusion: Pancreatic lesions were PET avid at baseline, and the rate of metabolic response was significantly higher fornab-P + Gem versus Gem alone at week 8 and for best response during study. Having a metabolic response was associatedwith longer survival, and more patients experienced a metabolic response than a RECIST-defined response.ClinicalTrials.gov: NCT00844649.

Original languageEnglish (US)
Article numbermdw020
Pages (from-to)648-653
Number of pages6
JournalAnnals of Oncology
Volume27
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

gemcitabine
Positron-Emission Tomography
Pancreas
Adenocarcinoma
Electrons
Survival
130-nm albumin-bound paclitaxel
Pancreatic Neoplasms
Disease Progression

Keywords

  • Gemcitabine
  • Metabolic response
  • Nab-paclitaxel
  • Pancreatic cancer
  • Positron emission tomography

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology
  • Oncology

Cite this

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. / Ramanathan, Ramesk K; Goldstein, D.; Korn, R. L.; Arena, F.; Moore, M.; Siena, S.; Teixeira, L.; Tabernero, J.; Van Laethem, J. L.; Liu, H.; McGovern, D.; Lu, B.; Von Hoff, D. D.

In: Annals of Oncology, Vol. 27, No. 4, mdw020, 01.04.2016, p. 648-653.

Research output: Contribution to journalArticle

Ramanathan, RK, Goldstein, D, Korn, RL, Arena, F, Moore, M, Siena, S, Teixeira, L, Tabernero, J, Van Laethem, JL, Liu, H, McGovern, D, Lu, B & Von Hoff, DD 2016, 'Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas', Annals of Oncology, vol. 27, no. 4, mdw020, pp. 648-653. https://doi.org/10.1093/annonc/mdw020
Ramanathan, Ramesk K ; Goldstein, D. ; Korn, R. L. ; Arena, F. ; Moore, M. ; Siena, S. ; Teixeira, L. ; Tabernero, J. ; Van Laethem, J. L. ; Liu, H. ; McGovern, D. ; Lu, B. ; Von Hoff, D. D. / Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. In: Annals of Oncology. 2016 ; Vol. 27, No. 4. pp. 648-653.
@article{83d439eb108644ce81f4471157079a05,
title = "Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas",
abstract = "In the phase III MPACT trial, nab-paclitaxel plus gemcitabine (nab-P + Gem) demonstrated superior efficacyversus Gem alone for patients with metastatic pancreatic cancer. We sought to examine the feasibility of positron emissiontomography (PET) and to compare metabolic response rates and associated correlations with efficacy in the MPACT trial.Patients and methods: Patients with previously untreated metastatic adenocarcinoma of the pancreas were randomized1:1 to receive nab-P + Gem or Gem alone. Treatment continued until disease progression by RECIST or unacceptable toxicity.Results: PET scans were carried out on the first 257 patients enrolled at PET-equipped centers (PET cohort). Most patients(252 of 257) had ≥ 2 PET-avid lesions, and median maximum standardized uptake values at baseline were 4.6 and 4.5 in thenab-P + Gem and Gem-alone arms, respectively. In a pooled treatment arm analysis, a metabolic response by PET (best responseat any time during study) was associated with longer overall survival (OS) (median 11.3 versus 6.9 months; HR, 0.56;P < 0.001). Efficacy results within each treatment arm appeared better for patients with a metabolic response. The metabolicresponse rate (best response and week 8 response) was higher for nab-P + Gem (best response: 72{\%} versus 53{\%},P = 0.002; week 8: 67{\%} versus 51{\%}; P = 0.014). Efficacy in the PET cohort was greater for nab-P + Gem versus Gem alone,including for OS (median 10.5 versus 8.4 months; hazard ratio [HR], 0.71; P = 0.009) and ORR by RECIST (31{\%} versus 11{\%};P < 0.001).Conclusion: Pancreatic lesions were PET avid at baseline, and the rate of metabolic response was significantly higher fornab-P + Gem versus Gem alone at week 8 and for best response during study. Having a metabolic response was associatedwith longer survival, and more patients experienced a metabolic response than a RECIST-defined response.ClinicalTrials.gov: NCT00844649.",
keywords = "Gemcitabine, Metabolic response, Nab-paclitaxel, Pancreatic cancer, Positron emission tomography",
author = "Ramanathan, {Ramesk K} and D. Goldstein and Korn, {R. L.} and F. Arena and M. Moore and S. Siena and L. Teixeira and J. Tabernero and {Van Laethem}, {J. L.} and H. Liu and D. McGovern and B. Lu and {Von Hoff}, {D. D.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1093/annonc/mdw020",
language = "English (US)",
volume = "27",
pages = "648--653",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas

AU - Ramanathan, Ramesk K

AU - Goldstein, D.

AU - Korn, R. L.

AU - Arena, F.

AU - Moore, M.

AU - Siena, S.

AU - Teixeira, L.

AU - Tabernero, J.

AU - Van Laethem, J. L.

AU - Liu, H.

AU - McGovern, D.

AU - Lu, B.

AU - Von Hoff, D. D.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - In the phase III MPACT trial, nab-paclitaxel plus gemcitabine (nab-P + Gem) demonstrated superior efficacyversus Gem alone for patients with metastatic pancreatic cancer. We sought to examine the feasibility of positron emissiontomography (PET) and to compare metabolic response rates and associated correlations with efficacy in the MPACT trial.Patients and methods: Patients with previously untreated metastatic adenocarcinoma of the pancreas were randomized1:1 to receive nab-P + Gem or Gem alone. Treatment continued until disease progression by RECIST or unacceptable toxicity.Results: PET scans were carried out on the first 257 patients enrolled at PET-equipped centers (PET cohort). Most patients(252 of 257) had ≥ 2 PET-avid lesions, and median maximum standardized uptake values at baseline were 4.6 and 4.5 in thenab-P + Gem and Gem-alone arms, respectively. In a pooled treatment arm analysis, a metabolic response by PET (best responseat any time during study) was associated with longer overall survival (OS) (median 11.3 versus 6.9 months; HR, 0.56;P < 0.001). Efficacy results within each treatment arm appeared better for patients with a metabolic response. The metabolicresponse rate (best response and week 8 response) was higher for nab-P + Gem (best response: 72% versus 53%,P = 0.002; week 8: 67% versus 51%; P = 0.014). Efficacy in the PET cohort was greater for nab-P + Gem versus Gem alone,including for OS (median 10.5 versus 8.4 months; hazard ratio [HR], 0.71; P = 0.009) and ORR by RECIST (31% versus 11%;P < 0.001).Conclusion: Pancreatic lesions were PET avid at baseline, and the rate of metabolic response was significantly higher fornab-P + Gem versus Gem alone at week 8 and for best response during study. Having a metabolic response was associatedwith longer survival, and more patients experienced a metabolic response than a RECIST-defined response.ClinicalTrials.gov: NCT00844649.

AB - In the phase III MPACT trial, nab-paclitaxel plus gemcitabine (nab-P + Gem) demonstrated superior efficacyversus Gem alone for patients with metastatic pancreatic cancer. We sought to examine the feasibility of positron emissiontomography (PET) and to compare metabolic response rates and associated correlations with efficacy in the MPACT trial.Patients and methods: Patients with previously untreated metastatic adenocarcinoma of the pancreas were randomized1:1 to receive nab-P + Gem or Gem alone. Treatment continued until disease progression by RECIST or unacceptable toxicity.Results: PET scans were carried out on the first 257 patients enrolled at PET-equipped centers (PET cohort). Most patients(252 of 257) had ≥ 2 PET-avid lesions, and median maximum standardized uptake values at baseline were 4.6 and 4.5 in thenab-P + Gem and Gem-alone arms, respectively. In a pooled treatment arm analysis, a metabolic response by PET (best responseat any time during study) was associated with longer overall survival (OS) (median 11.3 versus 6.9 months; HR, 0.56;P < 0.001). Efficacy results within each treatment arm appeared better for patients with a metabolic response. The metabolicresponse rate (best response and week 8 response) was higher for nab-P + Gem (best response: 72% versus 53%,P = 0.002; week 8: 67% versus 51%; P = 0.014). Efficacy in the PET cohort was greater for nab-P + Gem versus Gem alone,including for OS (median 10.5 versus 8.4 months; hazard ratio [HR], 0.71; P = 0.009) and ORR by RECIST (31% versus 11%;P < 0.001).Conclusion: Pancreatic lesions were PET avid at baseline, and the rate of metabolic response was significantly higher fornab-P + Gem versus Gem alone at week 8 and for best response during study. Having a metabolic response was associatedwith longer survival, and more patients experienced a metabolic response than a RECIST-defined response.ClinicalTrials.gov: NCT00844649.

KW - Gemcitabine

KW - Metabolic response

KW - Nab-paclitaxel

KW - Pancreatic cancer

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=84964636352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964636352&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdw020

DO - 10.1093/annonc/mdw020

M3 - Article

C2 - 26802153

AN - SCOPUS:84964636352

VL - 27

SP - 648

EP - 653

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 4

M1 - mdw020

ER -